A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)

A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT) is a phase 2 interventional study registered as NCT07471165 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 25 participants, started 2026-03-01 and due to reach its primary completion in 2029-03-01. Interventions recorded: PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation. Conditions listed: Locally Advanced Perihilar Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: "Diagnosed with intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, or gallbladder cancer.". Sites: China. No results are recorded here; the registry entry is the source.